Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 10/20 | 0.65 |
| ▸ | VIPR1 | P32241 | 7/20 | 0.65 |
| ▸ | GLP1R | P43220 | 3/20 | 0.60 |
| ▸ | GHSR | Q92847 | 2/20 | 0.60 |
| ▸ | ECE1 | P42892 | 1/20 | 0.60 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.59 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.58 |
| ▸ | CALCR | P30988 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623200 | 0.87 | RAMP3 (0.56) | VIPR2VIPR1GLP1RECE1MUS81 | |
| SCHEMBL29800212 | 0.87 | VIPR1 (0.65) | VIPR2VIPR1GLP1RECE1MUS81 | |
| SCHEMBL29412270 | 0.86 | VIPR2 (0.66) | VIPR2VIPR1GLP1RECE1MUS81 | |
| SCHEMBL29366375 | 0.86 | VIPR2 (0.64) | VIPR2VIPR1GLP1RECE1MUS81 | |
| SCHEMBL31683259 | 0.85 | TFPI (0.64) | VIPR2VIPR1 | |
| SCHEMBL29819496 | 0.85 | IL23R (0.60) | VIPR2VIPR1GLP1RNPY2R | |
| SCHEMBL30467092 | 0.84 | TFPI (0.62) | VIPR1GLP1R | |
| SCHEMBL34468124 | 0.84 | TFPI (0.60) | — | |
| SCHEMBL30120636 | 0.84 | TFPI (0.66) | VIPR1GLP1RNR3C1 | |
| SCHEMBL30721553 | 0.84 | TFPI (0.66) | VIPR1GLP1RECE1MUS81NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388973-A1 | MULTI-OMICS ASSESSMENT | PROGNOMIQ INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025227105-A1 | CLEAVABLE LINKERS WITH TUNABLE HALF-LIVES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| US-20240167070-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Ny-HYDROXY- OR Ny-AMINO-L-ASPARAGINE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-05-23 | — | — | US | disclosed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | disclosed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2022212362-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022186782-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Nγ-HYDROXY- OR Nγ-AMINO-L-ASPARAGINE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-09 | — | — | WO | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| US-20220213461-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-07-07 | — | — | US | disclosed |
| EP-3966321-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | Nanyang Technological University (SG) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | VIPR2 4130/4885VIPR1 3881/4885GLP1R 3793/4885 |
| US-20250388973-A1 | MULTI-OMICS ASSESSMENT | S100A4, APOL1, SAAL1 | VIPR2 4107/4885VIPR1 4096/4885GLP1R 4103/4885 |
| US-20240167070-A1 | METHODS FOR CYCLIZATION OF (POLY)PEPTIDES COMPRISING Ny-HYDROXY- OR Ny-AMINO-L-ASPARAGINE | ANPEP, DNPEP, ASNS | VIPR2 864/4885VIPR1 565/4885GLP1R 1151/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | VIPR2 4101/4885VIPR1 3893/4885GLP1R 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.